News Summary: $2.15B settlement in Protonix case

Published



THE DEAL: Two generic drugmakers will pay $2.15 billion to Pfizer Inc. and Takeda Pharmaceuticals to resolve a lawsuit over the heartburn drug Protonix.

THE LAUNCH: Teva Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries Ltd. started selling generic versions of Protonix before the patents supporting the drug expired. They hoped to get those patents overturned or reach a settlement that would allow them to start selling their versions before the patents expired.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.